1. Limited Emergence of Salmonella enterica Serovar Infantis Variants with Reduced Phage Susceptibility in PhagoVet-Treated Broilers.
- Author
-
Sevilla-Navarro, Sandra, Otero, Jennifer, López-Pérez, Júlia, Torres-Boncompte, Jan, Prucha, Tiago, De Gussem, Maarten, Silva, Daniela, Burgan, Julia, Catalá-Gregori, Pablo, Cortés, Pilar, and Llagostera, Montserrat
- Subjects
- *
TRANSMISSION electron microscopy , *NUCLEOTIDE sequencing , *SALMONELLA , *TREATMENT effectiveness , *FECES , *BACTERIOPHAGES , *SALMONELLA enterica - Abstract
Simple Summary: One of the main concerns associated with phage applications is the potential emergence of bacterial variants exhibiting reduced susceptibility to bacteriophages, which may jeopardize the success of such applications, as occurs with antibiotics. In this work, we studied the emergence of reduced-phage-susceptibility variants in broiler trials challenged with Salmonella enterica serovar Infantis and treated with the PhagoVet product. We characterized the bacteriophages composing the PhagoVet product at both a microscopic and genomic level, which displayed a broad host range of infection against 271 strains representing 18 Salmonella serovars. Our results indicate that the emergence of reduced-phage-susceptibility variants is unlikely to compromise the efficacy of oral PhagoVet against S. Infantis. Salmonella enterica serovar Infantis (S. Infantis) poses a growing issue in the poultry sector, with phage-based products emerging as a safe and effective control measure. This study investigated the emergence of reduced-phage-susceptibility variants (RPSV) of S. Infantis in PhagoVet-treated broilers, given that RPSV could undermine phage treatment efficacy. The bacteriophages in the PhagoVet product were characterized using transmission electron microscopy (TEM), genome sequencing, and infection profiling. Furthermore, two broiler trials were conducted: a challenge group (T1) and a challenge-and-treated group (T2). The S. Infantis infective dose was set at 104 and 106 colony-forming units (CFUs) per animal, with PhagoVet administration at 106 and 108 plaque-forming units (PFUs) per animal, in Trials 1 and 2, respectively. The results revealed that the four PhagoVet bacteriophages belonged to different genera. PhagoVet evidenced broad-spectrum efficacy against 271 strains representing 18 Salmonella serovars. In Trial 1, PhagoVet reduced bacterial counts in feces to nearly undetectable levels by day 42, with no RPSV detected. However, in Trial 2, three and five RPSVs were detected in feces and ceca, respectively. Consequently, PhagoVet demonstrated efficacy against S. Infantis in broilers, and the potential impact of RPSV is deemed unlikely to compromise its efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF